Brief: Argent Biopharma Enters Global Licensing Transaction
07/07/2026 02:28
BRIEF-Argent Biopharma Enters Global Licensing Transaction July 7 (Reuters) - Argent BioPharma Ltd RGT.AX:
ENTERS A GLOBAL LICENSING TRANSACTION FOR CANNEPIL WITH SPLASH BEVERAGE GROUP INC
TRANSACTION INCLUDES $5.5 MILLION UPFRONT CONSIDERATION FOR GLOBAL LICENSING RIGHTS
TO RECEIVE A 15% NET REVENUE ROYALTY ON FUTURE SBEV GLOBAL CANNEPIL REVENUES
Further company coverage: RGT.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Endovia Health Sciences
See all newsBrief: Endovia Health Sciences - Enters Letter Agreement With C/M Capital Master Fund On Oct 15, 2026 - SEC Filing
Brief: Endovia Health Sciences Enters Letter Agreement With C/M Capital Master Fund On Sept 18, 2026
Brief: Endovia Health Sciences Advances Cannepil FDA Submission, Expands Pipeline
Brief: Splash Beverage Reports Second Quarter 2026 Results And Highlights Strategic Transformation Toward Endovia Health Sciences
Expands Cannepil License To Veterinary Therapeutics